Summary:
Molbio Diagnostics shares debuted at ₹980 on both NSE and BSE, a 21.44% premium over the ₹807 IPO price. The ₹940 crore IPO was subscribed 70.26 times overall, led by QIBs at 186.39x. The company reported FY26 net profit of ₹166.59 crore on revenue of ₹1,445.69 crore. Its Truenat diagnostics platform has over 12,500 devices installed across more than 90 countries.
Molbio Diagnostics IPO Listing Day Highlights
Molbio Diagnostics made its stock market debut on Monday, August 17, 2026. The stock listed at ₹980 on both the NSE and BSE, a premium of 21.44% over the issue price of ₹807.
For investors who got an allotment, that listing price worked out to a gain of ₹3,114 per lot, taking the value of a single 18-share lot from ₹14,526 to ₹17,640.
This was a solid, well-received debut, and the stock held up reasonably well through the morning session, trading around ₹946.25 by mid-morning, still comfortably above the issue price, after touching an intraday high of ₹1,002.05 and a low of ₹925.80. The listing came on the back of an extraordinary bidding window that closed with the issue subscribed 70.26 times overall.
Find Out Latest Share price of Molbio
Subscription Status Recap
Molbio Diagnostics' IPO closed its three-day bidding window on August 12, 2026, with the issue subscribed 70.26 times overall.
| Category | Final Subscription |
| Qualified Institutional Buyers (QIB) | 186.39x |
| Non-Institutional Investors (NII) | 49.80x |
| Retail Individual Investors (RII) | 12.96x |
| Overall | 70.26x |
The ₹940 crore issue received bids for 57,32,14,536 shares against 81,58,529 shares on offer, according to NSE data. QIB demand was extraordinary at 186.39x, reflecting overwhelming institutional conviction, while NII closed at 49.80x and retail, though comparatively more measured, still closed a strong 12.96x.
Check Out Final Day Subscriptions for Molbio IPO
Molbio Diagnostics Financial Performance - FY26 Numbers
Molbio Diagnostics, incorporated in 2000, is a point-of-care molecular diagnostics company offering testing across 30 diseases, including tuberculosis, HPV, HIV, COVID-19, and hepatitis B and C, through its proprietary Truenat platform. As of March 31, 2026, over 12,500 Truenat devices were installed across more than 90 countries, with revenue primarily generated from device sales and recurring sales of proprietary Truenat test kits. The company has also expanded into digital imaging, digital pathology, and breast health screening through acquisitions, investments, and partnerships.
For the twelve months ended March 31, 2026, the company reported consolidated net profit of ₹166.59 crore on sales of ₹1,445.69 crore. This was a ₹939.70 crore IPO, made up of a fresh issue of ₹200 crore and an offer for sale of up to 91.66 lakh equity shares worth ₹739.70 crore by existing shareholders. The fresh issue proceeds are earmarked for capital expenditure toward R&D facilities and a Centre of Excellence, along with investment in plant and machinery for the company's Goa and Visakhapatnam facilities. Ahead of the IPO, on August 7, 2026, the Goa-based company, backed by Temasek and Motilal Oswal Private Equity, raised ₹281.5 crore from anchor investors, including Goldman Sachs, Mirae Asset, Nippon India Mutual Fund, Kotak Mutual Fund, BlackRock Global Funds, Tata Mutual Fund, WhiteOak Capital, ICICI Prudential Mutual Fund, Bajaj Life Insurance, and HDFC Life Insurance.
Also take a look at Allotment Status
Should You Hold, Buy More, or Sell Molbio Diagnostics After Listing?
Case for Holding
The stock delivered a solid listing gain of over 21%, and the underlying business is genuinely differentiated, a globally deployed diagnostics platform with over 12,500 devices installed across more than 90 countries, backed by marquee investors like Temasek and Motilal Oswal Private Equity. With strong anchor participation from names like Goldman Sachs and BlackRock ahead of the issue, and a healthy FY26 profit of ₹166.59 crore, holding through near-term volatility to participate in the company's global diagnostics growth story is a reasonable approach for allotted investors.
Case for Buying More on Listing
Demand for this issue was extraordinary, subscribed over 70 times overall, with QIB alone crossing 186 times subscription, among the strongest institutional responses seen in recent IPOs. That level of conviction reflects real confidence in Molbio's differentiated technology and global reach. For those who missed out on allotment, the stock's mid-morning trading levels, still meaningfully above the issue price but below the opening print, may offer a somewhat more measured entry point into a business with strong institutional backing.
Case for Booking Profit
The stock is up over 21% from its issue price on debut, though it has already pulled back from its intraday high of ₹1,002.05 to trade closer to ₹946 by mid-morning, showing some early profit-booking pressure. With such strong demand already reflected in the listing-day price, some investors may prefer to lock in the gain now rather than hold through the volatility typical of the first few sessions after a hot debut.
Molbio Diagnostics Share Price - What to Watch Next
Going forward, keep an eye on how the stock settles over its first full week, since the early pullback from the day's high to the mid-morning trading range suggests some profit-booking is already underway. Track the company's continued expansion of its Truenat device installations globally, and watch the next set of quarterly results to see whether the FY26 profit and revenue trajectory holds up. Given Molbio's position in point-of-care diagnostics, a sector with growing global demand for rapid, portable testing, near-term price moves are likely to be sensitive to both company-specific execution and broader healthcare and diagnostics sector sentiment in the weeks ahead.
